Clinical Trials Logo

Clinical Trial Summary

The purpose of this dose finding study is to evaluate the safety and efficacy of 2 different dose levels of CLR 131 in children, adolescents and young adults with relapsed or refractory high-grade glioma (HGG).


Clinical Trial Description

This study is designed to further evaluate the safety and tolerability of CLR 131 at the selected doses in children, adolescents and young adults with relapsed or refractory malignant high-grade glioma. It will also determine the therapeutic activity defined as progression free survival and overall survival, antitumor activity (treatment response) defined as the reduction in tumor volume and identify the recommended Phase 2/3 dose of CLR 131 in children, adolescents and young adults with relapsed or refractory HGG. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05610891
Study type Interventional
Source Cellectar Biosciences, Inc.
Contact Kate Oliver
Phone 608-327-8125
Email clinical@cellectar.com
Status Recruiting
Phase Phase 1
Start date October 1, 2023
Completion date September 2026

See also
  Status Clinical Trial Phase
Terminated NCT02305056 - Study of Tumor Metabolism by Isotopic Tagging in Patients With High-grade Glioma (CARBONOMIC) Phase 1
Not yet recruiting NCT06002711 - Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study
Recruiting NCT04299191 - Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT00548938 - Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM Phase 2
Completed NCT01644773 - Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) Phase 1
Recruiting NCT02239952 - HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors) N/A
Completed NCT00565721 - A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Phase 2
Recruiting NCT05929456 - Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid) Phase 1
Recruiting NCT04552756 - Seizures During Radiotherapy for High-grade Gliomas N/A
Not yet recruiting NCT04482933 - HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma Phase 2
Terminated NCT04730349 - A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer Phase 1/Phase 2
Completed NCT05873946 - Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery
Recruiting NCT02848794 - Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma Phase 1/Phase 2
Recruiting NCT06209567 - A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors Early Phase 1
Not yet recruiting NCT06201351 - Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction MRI
Recruiting NCT06118723 - The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Completed NCT00624728 - Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP) Phase 1/Phase 2
Terminated NCT04851834 - NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma Phase 1/Phase 2
Recruiting NCT04908267 - How the Precise Habitats Can Predict the IDH Mutation Status and Prognosis of the Patients With High-grade Gliomas
Completed NCT03458312 - Nurse-led Family and Network Consultations N/A